the Medicaid and NC Health Choice programs cover filgrastim-ayow injection, for subcutaneous or intravenous use
Blog Entry List
Effective with date of service March 15, 2022, the Medicaid and NC Health Choice programs cover naloxone hydrochloride injection for intramuscular or subcutaneous use.
Effective with date of service March 2, 2022, the Medicaid and NC Health Choice programs cover plasminogen, human-tvmh lyophilized powder for reconstitution.
Effective with date of service March 29, 2022, the Medicaid and NC Health Choice programs cover hepatitis b vaccine (recombinant) injectable suspension.
Effective with date of service Feb. 25, 2022, the Medicaid and NC Health Choice programs cover tebentafusp-tebn injection.
Effective with date of service Feb. 23, 2022, the Medicaid and NC Health Choice programs cover sirolimus protein-bound particles for injectable suspension (albumin-bound).
Effective with date of service Feb. 28, 2022, the Medicaid and NC Health Choice programs cover cabotegravir extended-release injectable suspension, for intramuscular use (Apretude).
Effective with date of service Jan. 27, 2022, the Medicaid and NC Health Choice programs cover triamcinolone acetonide injectable suspension.
Effective with date of service Feb. 7, 2022, the Medicaid and NC Health Choice programs cover faricimab-svoa.
Effective with date of service Feb 1, 2022, the Medicaid and NC Health Choice programs cover pemetrexed injection, for intravenous use (Pemfexy™).
Approved for treatment of mild to moderate COVID-19
An updated version of Clinical Coverage Policy 5B, Orthotics and Prosthetics with an effective date of Feb. 1, 2022, is posted.
Effective with date of service Dec. 22, 2021, Medicaid and NC Health Choice cover inclisiran injection, for subcutaneous use (Leqvio®).
Effective with date of service Dec. 30, 2021, Medicaid and NC Health Choice cover ropeginterferon alfa-2b-njft injection, for subcutaneous use (BESREMI®).
Effective with date of service Dec. 17, 2021, Medicaid and NC Health Choice cover efgartigimod alfa-fcab injection, for intravenous use (VYVGART™).